Version 1
: Received: 7 June 2024 / Approved: 10 June 2024 / Online: 11 June 2024 (08:12:13 CEST)
How to cite:
Coelingh Bennink, H. J.; Roos, E. P.; van Moorselaar, R. J. A.; van Melick, H. H.; Somford, D. M.; Roeleveld, T. A.; de Haan, T. D.; Reisman, Y.; Schultz, I. J.; Krijgh, J.; Debruyne, F. M. The Anti-Tumor Effects of the Fetal Estrogen Estetrol in Advanced Prostate Cancer. Preprints2024, 2024060646. https://doi.org/10.20944/preprints202406.0646.v1
Coelingh Bennink, H. J.; Roos, E. P.; van Moorselaar, R. J. A.; van Melick, H. H.; Somford, D. M.; Roeleveld, T. A.; de Haan, T. D.; Reisman, Y.; Schultz, I. J.; Krijgh, J.; Debruyne, F. M. The Anti-Tumor Effects of the Fetal Estrogen Estetrol in Advanced Prostate Cancer. Preprints 2024, 2024060646. https://doi.org/10.20944/preprints202406.0646.v1
Coelingh Bennink, H. J.; Roos, E. P.; van Moorselaar, R. J. A.; van Melick, H. H.; Somford, D. M.; Roeleveld, T. A.; de Haan, T. D.; Reisman, Y.; Schultz, I. J.; Krijgh, J.; Debruyne, F. M. The Anti-Tumor Effects of the Fetal Estrogen Estetrol in Advanced Prostate Cancer. Preprints2024, 2024060646. https://doi.org/10.20944/preprints202406.0646.v1
APA Style
Coelingh Bennink, H. J., Roos, E. P., van Moorselaar, R. J. A., van Melick, H. H., Somford, D. M., Roeleveld, T. A., de Haan, T. D., Reisman, Y., Schultz, I. J., Krijgh, J., & Debruyne, F. M. (2024). The Anti-Tumor Effects of the Fetal Estrogen Estetrol in Advanced Prostate Cancer. Preprints. https://doi.org/10.20944/preprints202406.0646.v1
Chicago/Turabian Style
Coelingh Bennink, H. J., Jan Krijgh and Frans M.J. Debruyne. 2024 "The Anti-Tumor Effects of the Fetal Estrogen Estetrol in Advanced Prostate Cancer" Preprints. https://doi.org/10.20944/preprints202406.0646.v1
Abstract
Background: Co-treatment of the fetal estrogen estetrol (E4) with androgen deprivation therapy (ADT) for advanced prostate cancer (PCa) may further inhibit endocrine PCa tumor stimulators including testosterone (T), prostate-specific antigen (PSA), follicle-stimulating hormone (FSH), and insulin-like growth factor-1 (IGF-1).
Methods: A Phase II, double-blind, randomized, placebo-controlled study in advanced PCa patients requiring ADT (the PCombi study) was conducted to assess the effect of E4 co-treatment with LHRH agonist ADT on total T, free T, PSA, FSH, and IGF-1. Patients starting ADT were randomized 2:1 to 40 mg E4 (n=41) or placebo (n=21) for 24 weeks. Analyses were performed on the per-protocol population (PP), using the Wilcoxon-rank sum and the Kruskal-Wallis test.
Results: The PP population consisted of 57 patients (37 ADT+E4; 20 ADT+placebo). All individual data of the four endocrine tumor stimulators are presented in figures in the paper and in supplementary tables, showing that E4 co-treatment almost completely suppressed FSH levels in all patients, on average by 98% versus 37% in the placebo group (p
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
,
,
